Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Specialty Pharmaceuticals Market (2026-2031) - Rising Prevalence of Chronic and Rare Diseases Drives Growth

globenewswire.com
ABBV AbbVie is listed as a key company in the specialty pharmaceuticals market, which is projected to grow significantly. The article does not provide specific sentiment for AbbVie. AMGN Amgen is identified as a key player in the growing specialty pharmaceuticals market, driven by biologics and advanced therapies. No specific sentiment is detailed for Amgen. AZN AstraZeneca is mentioned as a key company in the specialty pharmaceuticals market, which is expected to experience substantial growth. The article does not offer specific sentiment for AstraZeneca. BIIB Biogen is named as a significant company in the specialty pharmaceuticals market, which is poised for considerable growth. The article does not express specific sentiment for Biogen. BMRA BioMarin is mentioned as a key company in the specialty pharmaceuticals market, which is expected to grow substantially, particularly in rare disease therapies. No specific sentiment is provided for BioMarin. BMY Bristol Myers Squibb is listed as a key player in the specialty pharmaceuticals market, which is projected to grow significantly. The article does not offer specific sentiment for Bristol Myers Squibb. JNJ Johnson & Johnson (Janssen) is identified as a key company in the growing specialty pharmaceuticals market. The article does not provide specific sentiment for Johnson & Johnson. MRK Merck & Co. is mentioned as a key company in the specialty pharmaceuticals market, which is expected to see substantial growth. The article does not provide specific sentiment for Merck & Co. NVS Novartis is identified as a key player in the expanding specialty pharmaceuticals market. The article does not provide specific sentiment or performance details for Novartis. PFE Pfizer is mentioned as a key company in the specialty pharmaceuticals market, which is expected to grow substantially. The article does not offer specific sentiment for Pfizer. REGN Regeneron is listed as a key company in the specialty pharmaceuticals market, which is projected for significant growth. The article does not provide specific sentiment for Regeneron. SNY Sanofi is mentioned as a key company in the specialty pharmaceuticals market, which is expected to see substantial growth. The article does not provide specific sentiment for Sanofi. TEVA Teva is mentioned as a key company in the specialty pharmaceuticals market, with a focus on biosimilars. The article does not provide specific sentiment for Teva. VRTX Vertex Pharmaceuticals is listed as a key company in the specialty pharmaceuticals market, which is projected for significant growth. The article does not provide specific sentiment for Vertex.

Specialty Pharmaceuticals Market (2026-2031) - Rising Prevalence of Chronic and Rare Diseases Drives Growth Dublin, Aug. 28, 2026 (GLOBE NEWSWIRE) -- The "Specialty Pharmaceuticals - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

Specialty Pharmaceuticals Market to Reach USD 99.63 Billion by 2031, Growing at a 35.12% CAGR

The global specialty pharmaceuticals market was valued at USD 16.37 billion in 2025 and is projected to increase from USD 22.12 billion in 2026 to USD 99.63 billion by 2031. This represents a compound annual growth rate of 35.12% during the 2026-2031 forecast period. Market expansion is being driven by the rising prevalence of chronic and rare diseases, rapid innovation in biologics and gene therapies, broader use of biosimilars, and continued investment in specialty-pharmacy networks.

Chronic and Rare Diseases Accelerate Demand

More than 300 million people worldwide live with one of approximately 5,500 recognized rare diseases. Diagnostic rates remain below 50% in many low- and middle-income countries, indicating substantial unmet medical need. Falling next-generation sequencing costs are supporting earlier identification of monogenic disorders and expanding the addressable patient population for enzyme-replacement therapies, gene therapies, and other precision medicines.

Chronic disease prevalence is also increasing. Six in 10 U.S. adults have at least one chronic condition, strengthening demand for long-term treatments across oncology, immunology, endocrinology, and neurology. Regulatory support remains an important growth factor, with the U.S. Food and Drug Administration granting 46 orphan-drug designations in 2024. Accelerated approval pathways are helping innovative specialty drugs reach patients sooner, although manufacturers continue to face significant post-marketing evidence requirements.

Biologics, Biosimilars, and Advanced Therapies Reshape the Market

Biologics represented 60.53% of the specialty pharmaceuticals market in 2025, supported by strong demand for monoclonal antibodies, fusion proteins, and recombinant enzymes. These therapies remain particularly important in chronic disease management, where recurring treatment schedules and high refill frequency sustain long-term market revenue.

Gene and cell therapies currently account for less than 5% of specialty pharmaceutical revenue but are forecast to expand at a CAGR of 37.75% through 2031. Growth is expected as manufacturing capacity improves and development timelines become more efficient. Continued progress in gene editing and off-the-shelf cell therapy platforms could further address the capacity and turnaround limitations associated with patient-specific treatments.

Biosimilar adoption is also increasing rapidly. In the United States, adalimumab biosimilars achieved penetration of more than 90% by the fourth quarter of 2024. European prescribing policies continue to support biosimilar uptake, although differences in substitution and interchangeability rules create varying market-access conditions. Asia is also emerging as a major center for innovative biologic development and manufacturing investment.

High Treatment Costs Create Market-Access Pressure

The growth outlook remains strong, but rising treatment costs and payer cost-containment measures present significant challenges. Medicare's first negotiated drug prices produced average discounts of 79% for selected therapies. Changes to annual out-of-pocket limits are also shifting more financial responsibility to health plans and manufacturers, contributing to tighter formularies, additional step-therapy requirements, and increased scrutiny of specialty-drug coverage.

Gene-therapy pricing remains a central reimbursement issue because several treatments carry multimillion-dollar price tags while long-term durability data remain limited. International reference pricing, health technology assessments, outcomes-based agreements, and risk-sharing arrangements are expected to play a larger role in determining access. Complex cold-chain requirements and specialized handling needs may also constrain distribution, particularly in markets with limited healthcare infrastructure.

Oncology Maintains the Largest Application Share

Oncology accounted for 35.55% of the specialty pharmaceuticals market in 2025, supported by checkpoint inhibitors, antibody-drug conjugates, bispecific antibodies, and CAR-T therapies. The oncology segment is projected to exceed USD 40 billion by 2031 as development pipelines increasingly focus on tumor-agnostic indications and combination regimens.

Rare-disease therapies are expected to record a CAGR of 36.85% through 2031, making the segment one of the fastest-growing areas of the specialty pharmaceuticals market. Revenue could increase sixfold over the forecast period as accelerated regulatory pathways advance ultra-orphan candidates. Reimbursement models will remain distinct across applications: oncology contracts often emphasize survival outcomes, while rare-disease therapies frequently involve negotiations over exceptionally high per-patient costs.

Regional Specialty Pharmaceuticals Market Outlook

North America generated 46.62% of global specialty pharmaceutical revenue in 2025. The region benefits from high treatment utilization, established infusion-center networks, advanced diagnostic capabilities, and strong access to newly approved therapies. However, drug-price negotiations and reimbursement reforms are expected to moderate revenue growth.

Europe remains a leading market for biosimilar adoption. Pricing negotiations, health technology assessments, and joint clinical evaluations continue to influence launch strategies and reimbursement timelines. Several European countries have reduced pharmaceutical list prices substantially following early benefit assessments, while some gene therapies remain available through managed-access programs.

Asia-Pacific is forecast to deliver the fastest regional growth, advancing at a CAGR of 36.22% through 2031. China's expanding approval pipeline, India's growing biosimilar manufacturing sector, and accelerated regulatory pathways in Japan are supporting market development. Australia and South Korea are also broadening specialty-drug reimbursement, although aggressive risk-sharing negotiations may limit near-term revenue potential.

Overall, the specialty pharmaceuticals market is positioned for substantial expansion as advances in biologics, biosimilars, precision medicine, and gene and cell therapies transform treatment options. Continued growth will depend on manufacturers, regulators, healthcare providers, and payers balancing clinical innovation with affordability, manufacturing scalability, and equitable patient access.

Key Topics Covered:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Prevalence of Chronic & Rare Diseases

4.2.2 Rapid Expansion of Biologics & Biosimilars Pipeline

4.2.3 Growth of Integrated Specialty-Pharmacy Networks

4.2.4 Orphan-Drug "Priority Review Voucher" Arbitrage

4.2.5 Pay-For-Performance Contracts Unlocking Niche Access

4.3 Market Restraints

4.3.1 Escalating Treatment Costs & Payer Cost-Containment

4.3.2 Complex Cold-Chain & Handling Logistics

4.3.3 Fragmented Real-World-Evidence Standards Slowing Uptake

4.3.4 Sustainability Pressure on Single-Use Delivery Devices

4.4 Supply-Chain Analysis

4.5 Regulatory Landscape

4.6 Technological Outlook

4.7 Porter's Five Forces

4.7.1 Threat of New Entrants

4.7.2 Bargaining Power of Suppliers

4.7.3 Bargaining Power of Buyers

4.7.4 Threat of Substitutes

4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

5.1 By Application

5.1.1 Oncology

5.1.2 Immunology

5.1.3 Endocrinology

5.1.4 Infectious Diseases

5.1.5 Neurology

5.1.6 Rare & Orphan Disorders

5.1.7 Cardiovascular

5.1.8 Ophthalmology

5.2 By Drug Class

5.2.1 Biologics

5.2.2 Small-molecule specialty drugs

5.2.3 Gene & Cell Therapies

5.2.4 Peptide Therapeutics

5.3 By Mode of Administration

5.3.1 Injectable/ Parenteral

5.3.2 Oral

5.3.3 Intravitreal / Ocular

5.3.4 Others

5.4 By Distribution Channel

5.4.1 Hospital Pharmacies

5.4.2 Specialty Pharmacies

5.4.3 Online Pharmacies

5.5 By Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 United Kingdom

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 India

5.5.3.3 Japan

5.5.3.4 Australia

5.5.3.5 South Korea

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)

6.3.1 AbbVie

6.3.2 Amgen

6.3.3 AstraZeneca

6.3.4 Bayer AG

6.3.5 Biogen

6.3.6 BioMarin

6.3.7 Boehringer Ingelheim

6.3.8 Bristol Myers Squibb

6.3.9 CSL Behring

6.3.10 Eli Lilly

6.3.11 Gilead Sciences

6.3.12 GSK plc

6.3.13 Horizon Therapeutics

6.3.14 Johnson & Johnson (Janssen)

6.3.15 Merck & Co.

6.3.16 Moderna

6.3.17 Novartis

6.3.18 Novo Nordisk

6.3.19 Pfizer

6.3.20 Regeneron

6.3.21 Roche

6.3.22 Sanofi

6.3.23 Sarepta Therapeutics

6.3.24 Takeda

6.3.25 Teva

6.3.26 UCB Pharma

6.3.27 Vertex Pharmaceuticals

7 Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/fqa4lo

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.